Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
J Intern Med ; 280(5): 509-517, 2016 11.
Article in English | MEDLINE | ID: mdl-27237700

ABSTRACT

BACKGROUND: Studies have shown that lipoprotein(a) [Lp(a)], an important carrier of oxidized phospholipids, is causally related to calcific aortic valve stenosis (CAVS). Recently, we found that Lp(a) mediates the development of CAVS through autotaxin (ATX). OBJECTIVE: To determine the predictive value of circulating ATX mass and activity for CAVS. METHODS: We performed a case-control study in 300 patients with coronary artery disease (CAD). Patients with CAVS plus CAD (cases, n = 150) were age- and gender-matched (1 : 1) to patients with CAD without aortic valve disease (controls, n = 150). ATX mass and enzymatic activity and levels of Lp(a) and oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) were determined in fasting plasma samples. RESULTS: Compared to patients with CAD alone, ATX mass (P < 0.0001), ATX activity (P = 0.05), Lp(a) (P = 0.003) and OxPL-apoB (P < 0.0001) levels were elevated in those with CAVS. After adjustment, we found that ATX mass (OR 1.06, 95% CI 1.03-1.10 per 10 ng mL-1 , P = 0.001) and ATX activity (OR 1.57, 95% CI 1.14-2.17 per 10 RFU min-1 , P = 0.005) were independently associated with CAVS. ATX activity interacted with Lp(a) (P = 0.004) and OxPL-apoB (P = 0.001) on CAVS risk. After adjustment, compared to patients with low ATX activity (dichotomized at the median value) and low Lp(a) (<50 mg dL-1 ) or OxPL-apoB (<2.02 nmol L-1 , median) levels (referent), patients with both higher ATX activity (≥84 RFU min-1 ) and Lp(a) (≥50 mg dL-1 ) (OR 3.46, 95% CI 1.40-8.58, P = 0.007) or OxPL-apoB (≥2.02 nmol L-1 , median) (OR 5.48, 95% CI 2.45-12.27, P < 0.0001) had an elevated risk of CAVS. CONCLUSION: Autotaxin is a novel and independent predictor of CAVS in patients with CAD.


Subject(s)
Aortic Valve Stenosis/blood , Aortic Valve Stenosis/etiology , Coronary Artery Disease/blood , Coronary Artery Disease/complications , Lipoprotein(a)/blood , Phospholipids/blood , Phosphoric Diester Hydrolases/blood , Aged , Apolipoprotein B-100/blood , Case-Control Studies , Female , Humans , Male , Oxidation-Reduction , Risk Factors
2.
Diabetes Obes Metab ; 13(12): 1073-87, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21736687

ABSTRACT

Despite improvement of microvascular outcomes as a consequence of optimal glucose control in patients with type 2 diabetes, prevention of macrovascular complications is still a major challenge. Of interest, large-scale intervention studies (Action to Control Cardiovascular Risk in Diabetes, Action in Diabetes and Vascular Disease-Preterax and Diamicron Modified Release Controlled Evaluation and Veterans Affairs Diabetes Trial) comparing standard therapy versus more intensive glucose-lowering therapy failed to report beneficial impacts on macrovascular outcomes. Consequently, it is currently under debate whether the high doses of exogenous insulin that were administered in these trials to achieve strict target glucose levels could be responsible for these unexpected outcomes. Additionally, a potential role for plasma insulin levels in predicting macrovascular outcomes has emerged in patients with or without type 2 diabetes. These observations, combined with evidence from in vitro and animal experiments, suggest that insulin might have intrinsic atherogenic effects. In this review, we summarize clinical trials, population-based studies as well as data emerging from basic science experiments that point towards the hypothesis that the administration of high insulin doses might not be beneficial in patients with type 2 diabetes and established macrovascular disease.


Subject(s)
Blood Glucose/drug effects , Cardiovascular Diseases/etiology , Diabetes Complications/prevention & control , Diabetes Mellitus, Type 2/complications , Hypoglycemic Agents/adverse effects , Insulin/adverse effects , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/prevention & control , Clinical Trials as Topic , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Female , Humans , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Male , Middle Aged , Risk Factors
3.
Int J Obes (Lond) ; 34(2): 340-7, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19918249

ABSTRACT

OBJECTIVE: To test the hypothesis that for any given body mass index (BMI) category, active individuals would have a smaller waist circumference than inactive individuals. Our second objective was to examine the respective contribution of waist circumference and physical inactivity on coronary heart disease (CHD) risk. DESIGN: Prospective, population-based study with an 11.4-year follow-up. SUBJECTS: A total of 21 729 men and women aged 45-79 years, residing in Norfolk, UK. METHODS: During follow-up, 2191 CHD events were recorded. Physical activity was evaluated using a validated lifestyle questionnaire that takes into account both leisure-time and work-related physical activity. Waist circumference was measured and BMI was calculated for each participant. RESULTS: For both men and women, we observed that within each BMI category (<25.0, 25-30 and >or=30.0 kg m(-2)), active participants had a lower waist circumference than inactive participants (P<0.001). In contrast, within each waist circumference tertile, BMI did not change across physical activity categories (except for women with an elevated waist circumference). Compared with active men with a low waist circumference, inactive men with an elevated waist circumference had a hazard ratio (HR) for future CHD of 1.74 (95% confidence interval (CI), 1.34-2.27) after adjusting for age, smoking, alcohol intake and parental history of CHD. In the same model and after further adjusting for hormone replacement therapy use, compared with active women with a low waist circumference, inactive women with an elevated waist circumference had an HR for future CHD of 4.00 (95% CI, 2.04-7.86). CONCLUSION: In any BMI category, inactive participants were characterized by an increased waist circumference, a marker of abdominal adiposity, compared with active individuals. Physical inactivity and abdominal obesity were both independently associated with an increased risk of future CHD.


Subject(s)
Coronary Disease/etiology , Motor Activity/physiology , Obesity, Abdominal/complications , Sedentary Behavior , Smoking/adverse effects , Waist Circumference , Abdominal Fat/pathology , Aged , Body Mass Index , Female , Health Status , Humans , Male , Middle Aged , Prospective Studies , Risk Factors , Surveys and Questionnaires , United Kingdom
4.
Eur J Clin Nutr ; 63(12): 1419-24, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19756031

ABSTRACT

BACKGROUND/OBJECTIVES: Obesity is associated with an inflammatory state that is often characterized by elevated plasma C-reactive protein (CRP) levels. Although coffee is broadly consumed in Western societies, few studies have examined the relationship between obesity, coffee consumption and CRP levels. The objective of this study was to assess the relationship between obesity, coffee consumption and variation in CRP in postmenopausal, overweight/obese women with or without hormone replacement therapy (HRT) use. SUBJECTS/METHODS: Cross-sectional analyses of 344 healthy sedentary, overweight/obese postmenopausal women (mean age=57.1+/-6.4 years and mean body mass index (BMI)=36.1+/-3.9 kg/ m(2)). Plasma CRP levels were measured by a highly sensitive immunoassay that used monoclonal antibodies coated with polystyrene particles. Diet was assessed using the Food Intake and Analysis System semiquantitative food frequency questionnaire. RESULTS: Plasma CRP was positively associated with BMI (P<0.001) and negatively associated with coffee consumption (P

Subject(s)
C-Reactive Protein/metabolism , Coffee , Estrogen Replacement Therapy , Obesity/blood , Body Mass Index , C-Reactive Protein/analysis , Cross-Sectional Studies , Female , Humans , Middle Aged , Overweight/blood , Postmenopause
5.
Diabetologia ; 52(2): 213-7, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18972095

ABSTRACT

AIMS/HYPOTHESIS: We previously reported that the plasma levels of the endocannabinoid, 2-arachidonoylglycerol (2-AG), in a cohort of viscerally obese men are directly correlated with visceral adipose tissue (VAT) accumulation and metabolic risk factors including low HDL-cholesterol and high triacylglycerol. It is not known, however, if such correlations persist after vigorous lifestyle interventions that reduce metabolic risk factors. We analysed the changes in endocannabinoid levels in a subsample from the same cohort following a 1 year lifestyle modification programme, and correlated them with changes in VAT and metabolic risk factors. METHODS: Forty-nine viscerally obese men (average age 49 years, BMI 30.9 kg/m(2), waist 107.3 cm) underwent a 1 year lifestyle modification programme including healthy eating and physical activity. Plasma levels of 2-AG and the other most studied endocannabinoid, anandamide, were measured by liquid chromatography-mass spectrometry. Anthropometric and metabolic risk factors, including VAT, insulin resistance and glucose intolerance, HDL-cholesterol and triacylglycerol, were measured. RESULTS: Most risk factors were improved by the intervention, which led to a significant decrease in body weight (-6.4 kg, p < 0.0001), waist circumference (-8.0 cm, p < 0.0001) and VAT (-30%, p < 0.0001), and in plasma 2-AG (-62.3%, p < 0.0001) and anandamide (-7.1%, p = 0.005) levels. The decrease in levels of 2-AG but not those of anandamide correlated with decreases in VAT and triacylglycerol levels, and with the increase in HDL(3)-cholesterol levels. Multivariate analyses suggested that decreases in 2-AG and VAT were both independently associated with decreases in triacylglycerol. CONCLUSIONS/INTERPRETATION: This study shows that a strong correlation exists between 2-AG levels and high plasma triacylglycerol and low HDL(3)-cholesterol in viscerally obese men.


Subject(s)
Arachidonic Acids/blood , Glycerides/blood , Life Style , Obesity/blood , Obesity/rehabilitation , Adiponectin/blood , Adipose Tissue/anatomy & histology , Apolipoproteins/blood , Body Mass Index , Body Weight , C-Reactive Protein/metabolism , Endocannabinoids , Humans , Interleukin-6/blood , Leptin/blood , Lipids/blood , Male , Risk Factors , Triglycerides/blood , Waist Circumference , Weight Loss
6.
Heart ; 94(9): 1175-80, 2008 Sep.
Article in English | MEDLINE | ID: mdl-17932090

ABSTRACT

INTRODUCTION: Aortic stenosis (AS) is the most common valvular heart disease in westernized societies. AS is a disease process akin to atherosclerosis in which calcification and tissue remodelling play a crucial role. In patients with moderate/severe AS, we sought to determine whether the remodelling process would be in relationship with transvalvular gradients and circulating oxidised low-density lipoprotein (ox-LDL) levels. METHODS: In 105 patients with AS, the aortic valve and blood plasma were collected at the time of valve replacement surgery. The degree of valve tissue remodelling was assessed using a scoring system (Score: 1-4) and the amount of calcium within the valve cusps was determined. The standard plasma lipid profile, the size of LDL particles and the plasma level of circulating ox-LDL (4E6 antibody) were determined. RESULTS: After adjustment for covariables, aortic remodelling score was significantly related to transvalvular gradients measured by Doppler echocardiography before surgery. Patients with higher valve remodelling score had higher circulating ox-LDL levels (score 2: 27.3 (SEM 2.6) U/l; score 3: 32.2 (SEM 2.3) U/l; score 4: 38.3 (SEM 2.3) U/l; p = 0.02). After correction for age, gender, hypertension and HDL-C, the plasma level of ox-LDL remained significantly associated with the aortic valve remodelling score (p<0.001). The plasma level of ox-LDL was significantly associated with LDL-C (r = 0.41; p<0.001), apoB (r = 0.59; p<0.001), triglyceride (r = 0.39; p<0.001), Apo A-I (r = 0.23; p = 0.01) and cholesterol in small (<255 A) LDL particles (r = 0.22; p = 0.02). After correction for covariables, circulating ox-LDL levels remained significantly associated with apoB (p<0.001) and triglyceride (p = 0.01) levels. CONCLUSION: Increased level of circulating ox-LDL is associated with worse fibrocalcific remodelling of valvular tissue in AS. It remains to be determined whether circulating ox-LDL is a risk marker for a highly atherogenic profile and/or a circulating molecule which is actively involved in the pathogenesis of calcific aortic valve disease.


Subject(s)
Aortic Valve Stenosis/blood , Aortic Valve/pathology , Calcinosis/blood , Lipoproteins, LDL/blood , Aged , Aortic Valve Stenosis/etiology , Aortic Valve Stenosis/pathology , Apolipoproteins B/blood , Biomarkers/blood , Calcinosis/complications , Calcinosis/pathology , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cross-Sectional Studies , Echocardiography, Doppler , Female , Humans , Linear Models , Male , Statistics, Nonparametric , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL